Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Pharmacy Administration, Policy and Regulation (3)
- Chemicals and Drugs (2)
- Life Sciences (2)
- Pharmaceutical Preparations (2)
- Business (1)
-
- Business Law, Public Responsibility, and Ethics (1)
- Cognition and Perception (1)
- Health Law and Policy (1)
- Law (1)
- Mental and Social Health (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Psychology (1)
- Social and Behavioral Sciences (1)
- Substance Abuse and Addiction (1)
- Keyword
-
- Drug (2)
- Risk (2)
- Advisory committees (1)
- Analysis (1)
- Clinical trial (1)
-
- Communication (1)
- Drug trial (1)
- Drug trials (1)
- Experimental (1)
- Expert (1)
- FDA (1)
- Informed consent (1)
- Institutional review boards (1)
- Medication (1)
- Medicine (1)
- Pain medication (1)
- Patients (1)
- Pharmaceutical (1)
- Physicians (1)
- Policy (1)
- Prescription (1)
- Public (1)
- Regulation (1)
- Regulations (1)
- Restriction (1)
- Side effects (1)
Articles 1 - 6 of 6
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Book Review Of Baruch A. Brody, Ethical Issues In Drug Testing, Approval, And Pricing, Annalee Abelson
Book Review Of Baruch A. Brody, Ethical Issues In Drug Testing, Approval, And Pricing, Annalee Abelson
RISK: Health, Safety & Environment (1990-2002)
Review of Baruch A. Brody, Ethical Issues in Drug Testing, Approval, and Pricing (Oxford University Press 1995). Conclusions, index, introduction, preface. LC 94-4479; ISBN 0-19-508831-X. [268 pp. Cloth $35.00. 200 Madison Avenue, New York NY 10016.]
Book Review, Jennifer L. Frizzell
Book Review, Jennifer L. Frizzell
RISK: Health, Safety & Environment (1990-2002)
Review of the following: THOMAS SZASZ, OUR RIGHT TO DRUGS: THE CASE FOR A FREE MARKET. (Praeger 1992) [164 pp.] Notes, bibliography, name index, notes, preface, subject index. LC: 91-30378; ISBN: 0-275-94216-3. [Cloth $19.95. P.O. Box 5007, Westwood CT 06881-9990.]
Risk Perception And Drug Safety Evaluation, Ilan B. Vertinsky, Donald A. Wehrung
Risk Perception And Drug Safety Evaluation, Ilan B. Vertinsky, Donald A. Wehrung
RISK: Health, Safety & Environment (1990-2002)
The authors present a Risk communication framework based on a survey of empirical research concerning public Risk perceptions. They also apply it to the area of pharmaceutical regulation to suggest more effective regulatory strategies.
Pharmaceutical Risk And The Quality Of Life, Beat Hiltbrunner, Andreas Breitsprecher
Pharmaceutical Risk And The Quality Of Life, Beat Hiltbrunner, Andreas Breitsprecher
RISK: Health, Safety & Environment (1990-2002)
Quality-of-life research is briefly described and said to be in its infancy. However, the authors observe that such studies may, e.g., make it possible to better match patients and therapies. They also predict that, as scientific difficulties are overcome, the pharmaceutical industry will become more active in planning, implementing and evaluating such research.
Patient Perceptions Of Drug Risks And Benefits, Michael S. Brown, Linda J. Wastila, Carol I. Baras, Louis Lasagna
Patient Perceptions Of Drug Risks And Benefits, Michael S. Brown, Linda J. Wastila, Carol I. Baras, Louis Lasagna
RISK: Health, Safety & Environment (1990-2002)
This is a report of a pilot study conducted to examine patients' perceptions of drug Risks and benefits. While all of the factors influencing such perceptions are important, the findings about the extent to which views are affected by patient understanding of and confidence in regulatory oversight should be of professional interest to an especially broad audience.
An Empirical Argument For Nontechnical Public Members On Advisory Committees: Fda As A Model, Joseph L. Lakshmanan
An Empirical Argument For Nontechnical Public Members On Advisory Committees: Fda As A Model, Joseph L. Lakshmanan
RISK: Health, Safety & Environment (1990-2002)
A discussion of the results of two surveys of present and past members of Food and Drug Administration Advisory Committees. The views and understanding of the issues before various categories of membership are compared and contrasted. It appears that technical members of advisory committees would generally welcome more participation by persons who lack special subject matter expertise.